(2026). Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would be Eligible for Treatment Based on the South Korean Reimbursement Criteria. JEADV Clinical Practice.
Successfully copied to clipboard
Copying to clipboard failed
Chicago Style (17th ed.) Citation
"Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would Be Eligible for Treatment Based on the South Korean Reimbursement Criteria."
JEADV Clinical Practice 2026.
Successfully copied to clipboard
Copying to clipboard failed
MLA (9th ed.) Citation
"Efficacy of Lebrikizumab in Patients With Severe Atopic Dermatitis Who Would Be Eligible for Treatment Based on the South Korean Reimbursement Criteria."
JEADV Clinical Practice, 2026.
Successfully copied to clipboard
Copying to clipboard failed
Warning: These citations may not always be 100% accurate.